Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation

Not Applicable

Completed

• Conditions: Coronary Artery Disease
• Interventions: Device: Qvanteq bioactive coronary stent

• Registration Number: NCT02176265
• Lead Sponsor: Qvanteq AG

Brief Summary

Objective of this First in Man study is to assess feasibility and safety of Qvanteq's bioactive coronary stent for treatment of stable coronary artery disease patients with de novo coronary artery stenosis in native vessels.

The proprietary surface of Qvanteq's bioactive coronary stent improves the in-growth behavior of the stent in the treated vessel. In-vivo animal studies revealed fast in-growth (similar to BMS), which however is not resulting in excessive tissue overgrowth as observed in BMS but rather has an efficacy profile similar to drug-eluting stent (DES), meaning suppression of tissue overgrowth. This should reduce the risk of restenosis and thrombus formation despite the presence of a short term dual anti platelet therapy (DAPT). Furthermore, prolonged DAPT time as applied with current DES increases the bleeding risk of patients.

The study is a prospective, multicenter, open-label, single arm study; conducted in up to 6 cardiology centers in CH and NL. In total, approx. 35 patients will be enrolled. All patients will be treated with the Qvanteq's bioactive coronary stent. Clinical follow-up will occur at 1, 6 \& 12 months post-stent implantation. All patients will undergo angiography assessment (QCA) and Optical Coherence Tomography investigation (OCT) at baseline and at 6 months follow-up. Baseline OCT should be performed after the successfully completed angiographic procedure (documentary OCT). 1 and 12 months clinical follow-ups are conducted via telephone.

Primary Angiographic endpoint is in-stent Late Lumen Loss at 6 months; assessed by off-line QCA. Primary OCT endpoint is mean neointimal thickness at 6 months; assessed by off-line OCT analysis.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2014-06-25
• Study First Submitted QC: 2014-06-26
• Study First Posted: 2014-06-27
• Study Start: 2014-09
• Primary Completion: 2016-02
• Study Completion: 2016-08
• Status Verified: 2016-09
• Last Update Submitted: 2016-09-02
• Last Update Posted: 2016-09-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 31

Inclusion Criteria

• Subjects must be at least 18 years of age
• Evidence of myocardial ischemia without elevated cardiac biomarkers (e.g. stable or unstable angina with stable haemodynamic condition, silent ischemia demonstrated by positive territorial functional study)
• The patient has a planned intervention of one single de novo lesion in one or two separate major epicardial territories (LAD, LCX, or RCA).
• The lesion must have a visually estimated diameter stenosis of ≥ 50% and < 100%
• Lesion length must be ≤16 mm
• The vessel size must be between 2.5 and 3.5 mm
• Written informed consent
• The patient agrees to the follow-up visits including angiographic follow-up and OCT control at 6 months

Key

Exclusion Criteria

• Evidence of ongoing acute myocardial infarction (AMI) in ECG and/or elevated cardiac biomarkers (according to local standard hospital practice) have not returned within normal limits at the time of procedure.
• Patient suffered from stroke/TIA or myocardial infarction during the last 6 months
• LVEF <30%
• Platelet count <100,000 cells/mm3 or >400,000 cells/mm3, a WBC of <3,000 cells/mm3, or documented or suspected liver disease (including laboratory evidence of hepatitis)
• Known renal insufficiency (Creatinine clearance less than 30 mL/Min), or subject on dialysis, or acute kidney failure
• Patient undergoing planned surgery within 6 months with the necessity to stop ASA
• Patient requiring prolonged DAPT for other diagnoses (>1 month)
• History of bleeding diathesis or coagulopathy
• Patient requiring oral anticoagulation (Coumadin, NOAC)
• The patient is a recipient of a heart transplant
• Known hypersensitivity or contraindication to aspirin, heparin, clopidogrel or cobalt-chromium
• Other medical illness (e.g. cancer, stroke with neurological deficiency) or known history of substance abuse (alcohol, cocaine, heroin etc.) as per physician judgment that may cause non-compliance with the protocol or confound the data interpretation or is associated with a limited life expectancy
• Female of child bearing potential (age <50 years and last menstruation within the last 12 months), who did not underwent tubal ligation, ovariectomy or hysterectomy.
• Previous CABG

Angiographic Exclusion Criteria:

• Severe tortuous, calcified or angulated coronary anatomy of the study vessel that in the opinion of the investigator would result in suboptimal imaging or excessive risk of complication from placement of an OCT catheter
• Target lesion in left main stem.
• Target lesion involves a side branch > 2.0mm in diameter
• Aorto-ostial target lesion (within 3 mm of the aorta junction).
• Total occlusion or TIMI flow <3, prior to wire crossing
• The target vessel contains visible thrombus
• Restenotic lesion.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Qvanteq bioactive coronary stent system	Qvanteq bioactive coronary stent	Open-label, single arm, non-randomized study

Primary Outcome Measures

Name	Time	Method
In-stent Late Lumen Loss (LLL) assessed by off-line QCA	At 6 months after stent implantation
Mean neointimal thickness assessed by off-line OCT analysis	At 6 months after stent implantation

Secondary Outcome Measures

Name	Time	Method
Acute success (device and procedural)	At baseline
Acute lumen gain assessed by off-line QCA	At 6 months after stent implantation
In-segment Late Lumen Loss assessed by off-line QCA	At 6 months after stent implantation
Mean Lumen Diameter (MLD) assessed by off-line QCA	At 6 months after stent implantation
Stent thrombosis according to ARC definitions	Up to 12 months after stent implantation
Diameter stenosis assessed by off-line QCA	At 6 months after stent implantation
Binary restenosis (diameter stenosis > = 50%) assessed by off-line QCA	At 6 months after stent implantation
Prolapse area/volume assessed by off-line OCT analysis	At baseline
Mean/minimal lumen diameter/area/volume assessed by off-line OCT analysis	At baseline and at 6 months after stent implantation
Mean/minimal stent diameter/area/volume assessed by off-line OCT analysis	At baseline and at 6 months after stent implantation
Stent symmetry assessed by off-line OCT analysis	At baseline and at 6 months after stent implantation
Stent expansion assessed by off-line OCT analysis	At baseline and at 6 months after stent implantation
Incomplete strut apposition assessed by off-line OCT analysis	At baseline and at 6 months after stent implantation
In-stent neointimal hyperplasia volume obstruction (%) assessed by off-line OCT analysis	At 6 months after stent implantation
Neointimal hyperplasia area/volume assessed by off-line OCT analysis	At 6 months after stent implantation
Mean/maximal thickness of the struts coverage assessed by off-line OCT analysis	At 6 months after stent implantation
Percentage number of covered struts assessed by off-line OCT analysis	At 6 months after stent implantation
Percentage of incomplete apposed struts assessed by off-line OCT analysis	At 6 months after stent implantation
Healing score assessed by off-line OCT analysis	At 6 months after stent implantation
Device-oriented composite endpoints (cardiac death, MI not clearly attributable to a non-intervention vessel, clinically indicated target lesion revascularization)	At 1, 6 and 12 months after stent implantation
Myocardial infarction (Q-wave, Non q-wave)	At 1, 6 and 12 months after stent implantation
Clinically indicated revascularization of the target vessel	At 1, 6 and 12 months after stent implantation
Any revascularization	At 1, 6 and 12 months after stent implantation

Trial Locations

Locations (6)

Universitätsklinik für Kardiologie Schweizer Herz- und Gefässzentrum Bern; 🇨🇭 Bern, Switzerland

Thoraxcenter Erasmus MC Universitair Medisch Centrum Rotterdam; 🇳🇱 Rotterdam, Netherlands

Cardiologie interventionnelle HUG - Hôpitaux Universitaires de Genève; 🇨🇭 Geneva, Switzerland

Stadtspital Triemli Zürich Klinik für Kardiologie; 🇨🇭 Zürich, Switzerland

HerzKlinik Hirslanden; 🇨🇭 Zürich, Switzerland

Thoraxcentrum Twente, Medisch Spectrum Twente; 🇳🇱 Enschede, Netherlands